{'fraction_non_alphanumeric': 0.0467706013363029, 'fraction_numerical': 0.0400890868596882, 'mean_word_length': 4.726114649681529, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Herpes Simplex Virus in Solid Organ Transplantation

Epidemiology Herpes simplex virus type-1 and 2 (HSV-1, HSV-2) are aherpesviruses which establish latency in nerve root ganglia. Infection with HSV-1, the classic oro-labial herpes virus, is acquired from early childhood through adulthood, with prevalence in the United States of 44% in 12–19 year olds and approximately 80% by the age of 60 (1). Associated primarily with genital herpes, HSV-2 has a seroprevalence that increases rapidly at the age of sexual debut, infecting 1.6% of persons aged 14–19 years and 26.3% of persons aged 40–49 years in the United States (2). In recent years, HSV-1 is an increasing cause of genital lesions, though typically with less frequent recurrences (3,4). Most adult transplant patients are infected with HSV-1 or HSV-2, or both, with prevalence similar to the distribution by age in the general population.